Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.

Research output: Contribution to journalArticle

Abstract

To study frequency, possible baseline predictors, timing, and duration of sustained remission [SR; defined as 28-joint Disease Activity Score (DAS28) < 2.6 for at least 6 mos] in patients with established rheumatoid arthritis (RA) treated with different tumor necrosis factor (TNF) inhibitors [etanercept (ETN), infliximab (IFX), adalimumab (ADA)]. In addition, the aim was to compare (head-to-head) the effectiveness of individual drugs in patients receiving their first anti-TNF treatment.

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Rheumatology and Autoimmunity
Original languageEnglish
Pages (from-to)741-748
JournalJournal of Rheumatology
Volume42
Issue number5
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes

Related research output

Jon Thorkell Einarsson, 2018, Lund: Lund University: Faculty of Medicine. 103 p.

Research output: ThesisDoctoral Thesis (compilation)

View all (1)